Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novocure's stock keeps sliding, but the company continues to perform.

This Unstoppable Cancer-Treatment Company's Stock Is on Sale Now

Is it time to buy this stock nearly at its 52 week low?

This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping?

Skillz

Trupanion

3 Stocks Wall Street Thinks Will Soar 44% to 122% That You'll Want to Check Out

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021.

Novocure to Report Third Quarter 2021 Financial Results

Zai Lab Ltd.

ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)-- #GastricCancer--Novocure and Zai Lab announced that the last patient has been enrolled in a phase 2 pilot trial of TTFields plus chemotherapy in gastric cancer.

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Roche Holding AG

Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC). The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as a first-line treatment for mPDAC.

Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #pancreaticcancer--Novocure has entered into a clinical trial collaboration with Roche to evaluate TTFields as part of a novel combination to treat pancreatic cancer.

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields. Its product has reached maturity phase in core active markets, with an expansion in new geographies on the cards.

NovoCure: TTFields Generating Revenues And Creating Avenues For Further Growth

Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster.

This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--The U.S. FDA has granted breakthrough device designation to Novocure's NovoTTF-200T™ System for advanced liver cancer.

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021.

Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021.

Novocure Appoints Bill Burke as Chief Human Resources Officer

The company has several key data readouts on the way.

What's Next for Novocure?

Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected.

Here's Why Novocure Dipped 19% This Week

Investors are seeing red in the company's latest earnings report.

Why Novocure Tanked on Thursday

NovoCure Limited (NVCR) CEO Asaf Danziger on Q2 2021 Results - Earnings Call Transcript

NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates

Novocure Ltd (NASDAQ: NVCR) posted a net loss of $14.6 million in Q2, compared to a net income of $1.7 million a year ago. EPS came in at $(0.14), missing the consensus of $0.01 Q2 net revenues were $133.5 million, representing 15% Y/Y growth, missing the estimate of $141.9 million.

Novocure Stock Dips As Q2 Earnings Trail Estimates; Higher Costs Hit Bottom Line

Shares of NovoCure (NASDAQ:NVCR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 800.00% over the past year to ($0.14), which missed the estimate of $0.01.

NovoCure: Q2 Earnings Insights

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure reported financial results for the second quarter 2021, highlighting commercial strength and strategic investment.

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards?

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program.

Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the second quarter 2021 on July 29, 2021, before the U.S. financial markets open.

Novocure to Report Second Quarter 2021 Financial Results

The shares of Novocure Ltd (NASDAQ: NVCR) have received a price target decrease from $242 to $229 from Mizuho. These are the details.

NVCR Stock Price: $229 Target From Mizuho

NovoCure is an attractive, high-growth, oncology company with a large market opportunity. The shares are particularly volatile following yesterday's liver cancer study results, which has created an attractive high-income options trade opportunity.

News for Novocure Stock (NVCR)